Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24854258 | 0.89 | CHRM5 (0.39) | CHRM5ADRA2CACHEOPRM1OPRL1 | |
| SCHEMBL19959015 | 0.86 | CHRM5 (0.37) | CHRM5ADRA2CACHEOPRM1OPRL1 | |
| SCHEMBL25134370 | 0.86 | GBA1 (0.36) | ACHEGBA1GNAO1HTR4ARG1 | |
| SCHEMBL24866010 | 0.83 | GBA1 (0.36) | CHRM5ADRA2CACHEOPRM1OPRL1 | |
| SCHEMBL2792355 | 0.80 | CACNA2D1 (0.40) | CHRM5ADRA2CACHEGBA1GNAO1 | |
| SCHEMBL25143821 | 0.80 | OPRM1 (0.32) | CHRM5ADRA2CACHEOPRM1OPRL1 | |
| SCHEMBL26138918 | 0.80 | CYP1A2 (0.33) | CHRM5ADRA2CACHEOPRM1OPRL1 | |
| SCHEMBL21933176 | 0.78 | OPRM1 (0.36) | CHRM5ADRA2CACHEOPRM1OPRL1 | |
| SCHEMBL21933964 | 0.78 | CHRM5 (0.36) | CHRM5ADRA2CACHEOPRM1OPRL1 | |
| SCHEMBL24854223 | 0.78 | CYP1A2 (0.33) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CHRM5 4309/4885ADRA2C 4526/4885ACHE 2447/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | CHRM5 4583/4885ADRA2C 4431/4885ACHE 3585/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CHRM5 4309/4885ADRA2C 4526/4885ACHE 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.